APA (7th ed.) Citation

Krause G, Hassenrück F, & Hallek M. (2018). Copanlisib for treatment of B-cell malignancies: The development of a PI3K inhibitor with considerable differences to idelalisib. Dove Medical Press.

Chicago Style (17th ed.) Citation

Krause G, Hassenrück F, and Hallek M. Copanlisib for Treatment of B-cell Malignancies: The Development of a PI3K Inhibitor with Considerable Differences to Idelalisib. Dove Medical Press, 2018.

MLA (9th ed.) Citation

Krause G, et al. Copanlisib for Treatment of B-cell Malignancies: The Development of a PI3K Inhibitor with Considerable Differences to Idelalisib. Dove Medical Press, 2018.